Ready To Welcome To...
Health Care: Drugs
AMAG Pharmaceuticals Inc. (AMAG: NASDAQ)
$22.25 0.31 | 1.41%
05/24/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 60.60 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.67 | 0.89 | 0.98 |
| Price to Sales (TTM) | 5.47 | 4.12 | 1.42 |
| Price to Book (MRQ) | 2.80 | 4.12 | 2.41 |
| Price to Tangible Book (MRQ) | 2.80 | 25.12 | 5.08 |
| Price to Cash Flow (TTM) | -206.00 | 25.80 | 9.80 |
| Price to Free Cash Flow (TTM) | n.a. | 58.70 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.20 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.30 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 24.08 | 2.80 |
| Payout Ratio (TTM) | 0.00 | 24.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 15.50 | 11.40 | 0.30 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 39.40 | 7.50 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 122.19 | 0.89 | 3.66 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 30.20 | 98.00 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 30.20 | 98.00 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | 8.04 |
| Capital Spending - 5 Yr Growth Rate (%) | -49.42 | -10.25 | 3.85 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 8.40 | 2.10 | 1.10 |
| Current Ratio (MRQ) | 9.20 | 2.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.38 | 0.73 |
| Total Debt to Equity (MRQ) | 0.00 | 0.49 | 0.86 |
| Interest Coverage (TTM) | n.a. | 81.30 | 6.80 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 90.20 | 64.70 | 47.70 |
| Gross Margin - 5 Yr Avg | 94.30 | 63.60 | 47.00 |
| EBITD Margin (TTM) | -1.10 | 22.90 | 19.40 |
| EBITD - 5 Yr Avg | -168.02 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -10.30 | 15.80 | 11.70 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.40 | 10.20 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -9.40 | 0.09 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.00 | 6.40 |
| Return on Assets (TTM) | -3.30 | 5.00 | 3.30 |
| Return on Assets - 5 Yr Avg | -26.60 | 3.90 | 2.30 |
| Return on Investment (TTM) | -4.80 | 6.40 | 8.70 |
| Return on Investment - 5 Yr Avg | -35.60 | 5.30 | 6.00 |
| Efficiency | |||
| Revenue/Employee (TTM) | 680,450.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | -63,791.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | 11.50 | 7.00 | 7.90 |
| Inventory Turnover (TTM) | 0.70 | 2.80 | 7.70 |
| Asset Turnover (TTM) | 0.30 | 0.60 | 0.40 |
Portfolios with AMAG
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- UserPelican Watch
- UserPART 1 JPMorgan 28th Annual...
- UserPART 1 JPMorgan 27th Annual...
- Userileana
- UserShawen Portfolio 1
- Userfiallo Portfolio 1
Latest AMAG Headlines from TheStreet
- Kudos To Keryx, But Can Zerenex Zing? 01.28.13 | 10:01 am
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- 3 Unusual-Volume Stocks Moving Higher 11.01.12 | 02:11 pm
- AMAG Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.10.12 | 03:09 pm
- AMAG Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.26.12 | 11:07 am
- AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript) 07.20.12 | 01:07 am
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Insiders Trading AMAG, CLWR, GTXI 03.06.12 | 10:03 am
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for AMAG
- AMAG Pharmaceuticals Announces Positive Preliminary Results From An Extension Study Evaluating The Safety And Efficacy Of Repeat Dosing With Ferumoxytol In Patients With Persistent Or Recurring Iron Deficiency Anemia, Regardless Of The Underlying Cause - Business Wire 03.15.13 | 06:03 am
- AMAG Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Feraheme Label Expansion To Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron - Business Wire 03.06.13 | 08:03 am
- AMAG Announces Fourth Quarter And Year End 2012 Financial Results - Business Wire 03.01.13 | 08:03 am
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Healthcare Conferences - Business Wire 02.21.13 | 04:02 pm
- Branham Law, LLP Investigates AMAG Pharmaceuticals On Behalf Of Stockholders - Business Wire 02.11.13 | 04:02 pm
- AMAG Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 05:02 pm
- AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results And 2013 Financial Guidance - Business Wire 01.06.13 | 07:01 am
- AMAG Pharmaceuticals Appoints Greg Madison As Chief Commercial Officer - Business Wire 01.02.13 | 08:01 am
- AMAG Pharmaceuticals, Inc. To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.26.12 | 08:12 am
- AMAG Pharmaceuticals Announces FDA Submission Of A Supplemental New Drug Application For Feraheme - Business Wire 12.24.12 | 08:12 am
Partner Headlines for AMAG
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.10.12 | 09:10 am
- AMAG Beats Expectations - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.27.12 | 09:07 am
- Akamai Tech REITERATED at Hold and 2 Must-See Reiterated Ratings - Wall St. Cheat Sheet 07.26.12 | 02:07 am
- AMAG Beats Riding on Feraheme Sales - Analyst Blog - Zacks 05.02.12 | 10:05 am
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- Israel Englander's Stock Picks With Insider Purchases - Seeking Alpha 01.18.12 | 09:01 am
- 17 Breakout Stocks Boosted By Insiders - Seeking Alpha 12.30.11 | 04:12 pm
- McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23 - Benzinga 12.12.11 | 01:12 pm
